Evidence map›Paper›PMID 32166512›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.

Christian J Konopka, Marcin Woźniak, Jamila Hedhli, Anna Siekierzycka, Jarosław Skokowski, Rafał Pęksa, Marcin Matuszewski, Gnanasekar Munirathinam, Andre Kajdacsy-Balla, Iwona T Dobrucki and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Christian J KonopkaDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Marcin WoźniakBeckman Institute for Advanced Science and Technology, Urbana, IL, USA.
Jamila HedhliDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA.
Anna SiekierzyckaDepartment of Medical Laboratory Diagnostics - Biobank, Medical University of Gdansk, Gdansk, Poland.
Jarosław SkokowskiDepartment of Medical Laboratory Diagnostics - Biobank, Medical University of Gdansk, Gdansk, Poland.
Rafał PęksaDepartment of Pathology, Medical University of Gdansk, Gdansk, Poland.
Marcin MatuszewskiDepartment of Urology, Medical University of Gdansk, Gdansk, Poland.
Gnanasekar MunirathinamDepartment of Biomedical Sciences, University of Illinois College of Medicine, Rockford, IL, USA.
Andre Kajdacsy-BallaDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
Iwona T DobruckiBeckman Institute for Advanced Science and Technology, Urbana, IL, USA.
Leszek KalinowskiDepartment of Medical Laboratory Diagnostics - Biobank, Medical University of Gdansk, Gdansk, Poland.
Lawrence W DobruckiDepartment of Bioengineering, University of Illinois at Urbana-Champaign, Urbana, IL, USA. dobrucki@illinois.edu.ORCID http://orcid.org/0000-0002-6807-217X
Gdańsk Medical University · PLUniversity of Illinois Urbana-Champaign · USIllinois College · USUniversity of Illinois Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCurrent screening and monitoring of prostate cancer (PCa) is insufficient, producing inaccurate diagnoses. Presence of the receptor for advanced glycation end-products (RAGE) is associated with signature characteristics of PCa development such as cell proliferation, anchorage-independent growth, angiogenesis, migration, invasion, and poor patient survival. Therefore, we developed a preclinical multimodal imaging strategy targeted at RAGE to diagnose and monitor PCa.

methodsIn this work, RAGE-targeted multimodal nanoparticles (64Cu-Cy5-G4-CML) were synthesized and rendered functional for nuclear and optical imaging using previously established methods. The probe's binding affinity and targeting specificity was assessed in androgen-dependent (LNCaP) and androgen-independent (DU145) prostate cancer cells using flow cytometry and confocal microscopy. In vivo PET-CT imaging was used to evaluate RAGE levels in DU145 and LNCaP xenograft models in mice. Then, tumors were excised post-imaging for histological staining and autoradiography to further assess RAGE levels and targeting efficiency of the tracer. Finally, RAGE levels from human PCa samples of varying Gleason Scores were evaluated using Western blot and immunohistochemical staining.

resultsPCa cell culture studies confirmed adequate RAGE-targeting with 64Cu-Cy5-G4-CML with K

conclusionsOur study has shown that RAGE-targeted cancer imaging is feasible and could significantly impact PCa management.

Indexed as

Copper RadioisotopesProstatic NeoplasmsAnimalsHumansMaleMicePositron Emission Tomography Computed TomographyReceptor for Advanced Glycation End ProductsCopper-64Copper RadioisotopesReceptor for Advanced Glycation End ProductsCancerInflammationMolecular imagingMultimodal imagingPET-CTRAGEReceptor for advanced glycation end-products

Identifiers

PMID32166512
OpenAlexW3011512422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.